Compile Data Set for Download or QSAR
maximum 50k data
Found 240 of ic50 data for polymerid = 769
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493096(N-((1H-imidazol-2-yl)methyl)-2-(1-((1r,4r)-4-(cyan...)
Affinity DataIC50:  12nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50:  12.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505104(US11066406, A)
Affinity DataIC50:  12.4nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493067(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  12.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493258(2-(8-chloro-1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-...)
Affinity DataIC50:  13.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  13.3nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505105(US11066406, B)
Affinity DataIC50:  13.4nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM420028(US10487083, Example B)
Affinity DataIC50:  13.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493279(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  13.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493259(2-(8-bromo-1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-1...)
Affinity DataIC50:  16.6nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493156((EZ)—N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl...)
Affinity DataIC50:  18.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493126(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  18.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493101(2-((1r,4r)-4-(2-(Thiazol-4-ylmethyl)imidazo[4,5-d]...)
Affinity DataIC50:  19.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493080(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  20.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505111(US11066406, Ex. 5)
Affinity DataIC50:  23.1nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387822(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  23.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387822(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  23.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493269(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  24.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  28.2nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  28.2nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505112(US11066406, Ex. 6)
Affinity DataIC50:  28.2nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493143(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387828(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  30.3nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505117(US11066406, Ex. 11)
Affinity DataIC50:  30.3nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387828(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  30.3nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527404(CHEMBL4514898 | US10981911, Example 62)
Affinity DataIC50:  30.6nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527409(CHEMBL4447497 | US10981911, Example 58)
Affinity DataIC50:  31.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493079(N-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-2-(1-((1r,4r...)
Affinity DataIC50:  31.8nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493088(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  32.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493116(2-((1r,4r)-4-(2-(1H-Imidazol-2-yl)imidazo[4,5-d]py...)
Affinity DataIC50:  32.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493169(Diethyl 4-(2-(1-((1r,4r)-4-(cyanomethyl)cyclohexyl...)
Affinity DataIC50:  32.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493070(2-((1r,4r)-4-(2-(Oxazol-4-yl)imidazo[4,5-d]pyrrolo...)
Affinity DataIC50:  33.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]py...)
Affinity DataIC50:  33.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505108(US11066406, Ex. 2)
Affinity DataIC50:  33.9nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]py...)
Affinity DataIC50:  33.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493087(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  36.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493075(2-((1r,4r)-4-(2-(2H-1,2,3-Triazol-4-yl)imidazo[4,5...)
Affinity DataIC50:  37.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527407(CHEMBL4582390 | US10981911, Example 33)
Affinity DataIC50:  38nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493083(N-(4-Cyanobicyclo[2.2.1]heptan-1-yl)-2-(1-((1r,4r)...)
Affinity DataIC50:  38.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493097(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  38.8nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493107(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  38.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493114(4-(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-di...)
Affinity DataIC50:  42nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387825(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  42.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493073(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  43.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493100(1-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihy...)
Affinity DataIC50:  47nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493281(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  47.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493068(2-((1r,4r)-4-(2-(1H-1,2,4-Triazol-3-yl)imidazo[4,5...)
Affinity DataIC50:  48.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493065(2-((1r,4r)-4-(2-(2-Oxo-2-(4-(trifluoromethyl)piper...)
Affinity DataIC50:  49.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505106(US11066406, C)
Affinity DataIC50:  49.7nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50434787(CHEMBL2386635 | US10487083, Example C | US10703751...)
Affinity DataIC50:  49.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 240 total ) | Next | Last >>
Jump to: